A disease-relevant high-content screening assay to identify anti-inflammatory compounds for Use in cystic fibrosis

Journal of Biomolecular Screening

Volumn 15, Issue 10, 2010, Pages 1204-1210

  Giddings, Angela M ^a   Maitra, Rangan ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

CFTR; cystic fibrosis; HCS; HTS; inflammation; NF B

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; BECLOMETASONE; CEFIXIME; DELTA1 HYDROCORTISONE 21; DESOXIMETASONE; DIMETHYL SULFOXIDE; FLUTICASONE PROPIONATE; HALOMETASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; LOTEPREDNOL ETABONATE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MLS 000758292; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG POTENCY; DRUG SCREENING; EPITHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; PNEUMONIA; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTI-INFLAMMATORY AGENTS; BRONCHI; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; NF-KAPPA B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SMALL MOLECULE LIBRARIES;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 78650146676     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110384612     Document Type: Article

References (27)

1. Tuchman LK, Schwartz LA, Sawicki GS, Britto MT: Cystic fibrosis and transition to adult medical care. Pediatrics 2010 ; 125: 566-573.
2. Lommatzsch ST, Aris R.: Genetics of cystic fibrosis. Semin Respir Crit Care Med 2009 ; 30: 531-538.
3. Verkman AS, Lukacs GL, Galietta LJ: CFTR chloride channel drug discovery: inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des 2006 ; 12: 2235-2247.
4. Turcios NL: Cystic fibrosis: an overview. J Clin Gastroenterol 2005 ; 39: 307-317.
5. Dodd ME, Prasad SA: Physiotherapy management of cystic fibrosis. Chron Respir Dis 2005 ; 2: 139-149.
6. Zhang Z., Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM: Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 2005 ; 73: 7151-7160.
7. Wu Q., Lu Z., Verghese MW, Randell SH: Airway epithelial cell tolerance to Pseudomonas aeruginosa. Respir Res 2005 ; 6: 26.
8. Buchanan PJ, Ernst RK, Elborn JS, Schock B.: Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem Soc Trans 2009 ; 37: 863-867.
9. Bonfield TL, Konstan MW, Berger M.: Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999 ; 104: 72-78.
10. Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003 ; 168: 918-951.
11. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW,, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000 ; 342: 851-859.
12. Konstan MW, Byard PJ, Hoppel CL, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995 ; 332: 848-854.
13. Saadane A., Soltys J., Berger M.: Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol 2006 ; 117: 1163-1169.
14. Wright JG, Christman JW: The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003 ; 2: 211-219.
15. Prescott WA Jr, Johnson CE: Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005 ; 25: 555-573.
16. Gruenert DC, Willems M., Cassiman JJ, Frizzell RA: Established cell lines used in cystic fibrosis research. J Cyst Fibros 2004 ; 3 (suppl 2). 191-196.
17. Maitra R., Porter MA, Huang S., Gilmour BP: Inhibition of NFkappaB by the natural product Withaferin A in cellular models of cystic fibrosis inflammation. J Inflamm (Lond) 2009 ; 6: 15.
18. Mohan R., Hammers HJ, Bargagna-Mohan P., Zhan XH, Herbstritt CJ, Ruiz A.,, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004 ; 7: 115-122.
19. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
20. Muir A., Soong G., Sokol S., Reddy B., Gomez MI, Van Heeckeren A.,, et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2004 ; 30: 777-783.
21. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J., Griffin S.,, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005 ; 174: 1638-1646.
22. Becker MN, Sauer MS, Muhlebach MS, Hirsh AJ, Wu Q., Verghese MW,, et al. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med 2004 ; 169: 645-653.
23. Moskowitz SM, Gibson RL, Effmann EL: Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol 2005 ; 35: 739-757.
24. Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000 ; 117: 1482-1487.
25. Dezateux C., Walters S., Balfour-Lynn I.: Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000 ;(2). CD001915.
26. Oermann CM: Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Curr Opin Investig Drugs 2001 ; 2: 900-906.
27. Chinuck RS, Fortnum H., Baldwin DR: Appetite stimulants in cystic fibrosis: a systematic review. J Hum Nutr Diet 2007 ; 20: 526-537.